loperamide and Leanness

loperamide has been researched along with Leanness in 1 studies

Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number of Urge Urinary Incontinence (UUI) Episodes

The primary outcome is the change from baseline in mean number of UUI episodes over the first 6-month visit period (1, 2, 3, 4, 5 and 6 month assessments); and is measured using 3-day bladder diaries administered monthly for the first 6 month visit period. (NCT01502956)
Timeframe: 6 Months

Quality of Life (HUI-3)

Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the Health Utility Index, Version 3 (HUI-3). The HUI 3 scale has a range from 0 to 1 with higher scores representing better health. (NCT01502956)
Timeframe: 6 Months

Quality of Life (IIQ-SF)

Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in the mean Incontinence Impact Questionnaire short form (IIQ-SF) score. The IIQ-SF scale has a range from 0 to 100 with higher scores indicating a worse quality of life. (NCT01502956)
Timeframe: 6 Months

Quality of Life (UDI-SF)

Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in mean Urinary Distress Inventory Short Form (UDI-SF) score. The UDI-SF scale has a range from 0 to 100 with higher scores indicating greater distress. (NCT01502956)
Timeframe: 6 Months

Treatment Satisfaction (OAB-SATq Treatment Preference)

"Treatment preference as measured by the Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) at 6 months (6 month assessment).OAB-SATq treatment preference is a binary outcome that is classified as yes if a participant answers either Slight preference for the treatment I am receiving now or Definitely prefer the treatment I am receiving now to the question Do you prefer the treatment that you received since entering this study to the treatment you received before the study?" (NCT01502956)
Timeframe: 6 Months

Change in Overactive Bladder

Change in mean Overactive Bladder Questionnaire Short Form (OABq-SF) score throughout baseline to the first 6-month visit (1, 2, 3, 4, 5, and 6-month assessments). Values range from 0 to 100 with higher scores on the symptom scale indicating greater severity of symptoms and higher scores on the quality of life scale indicating a better quality of life. (NCT01502956)
Timeframe: 6 Months

Number of Participants With Improvement of Bladder Function and Urinary Leakage

Proportion of subjects who report adequate improvement of their bladder function and urinary leakage with the Patient Global Impression of Improvement Questionnaire (PGI-I) at 6 months. Adequate improvement is defined as a rating of 1, 2, or 3 (better) on the patient-reported measure of perceived improvement with treatment on a scale of 1 (very much better) to 7 (very much worse). (NCT01502956)
Timeframe: 6 Months

Severity of Urge Incontinence Symptoms

Severity of urge incontinence symptoms at 6 month visit period as measured by the Sandvik questionnaire. The Sandvik score is a patient-reported measure of incontinence severity as assessed on a scale of slight (1-2), moderate (3-6), severe (8-9), very severe (12) to severe (10-12) using a standard scoring algorithm. (NCT01502956)
Timeframe: 6 Months

Treatment Satisfaction (OAB-SATq Treatment Satisfaction, Adverse Effects, Treatment Endorsement, and Convenience)

Treatment satisfaction as measured by the mean Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) score at 6 months (6 month assessment). The OAB-SATq score ranges from 0 to 100 and includes 5 subscales: treatment satisfaction, side effects, treatment endorsement, convenience, and treatment preference, with higher scores reflecting better satisfaction. (NCT01502956)
Timeframe: 6 months

Urinary Frequency and Nocturia

Change in mean number of urinary incontinence episodes (any type) and nocturia episodes from baseline over the first 6-month visit period (1, 2, 3, 4, 5, and 6-month assessments) as measured by the 3 day bladder diary. (NCT01502956)
Timeframe: 6 Months

Trials

1 trial available for loperamide and Leanness